Core Viewpoint - DJS Law Group is investigating Agilon Health, Inc. for potential violations of securities laws following significant leadership changes and a withdrawal of earnings guidance, which led to a sharp decline in the company's stock price [1][2]. Investigation Details - The investigation centers on whether Agilon made misleading statements or failed to disclose critical information to investors [2]. - On August 4, 2025, Agilon announced the resignation of President, CEO, and Board Director Steven Sell, which coincided with the release of its second quarter 2025 earnings results [2]. - Agilon also withdrew its previous full year 2025 earnings guidance, resulting in a more than 27% drop in shares during after-hours trading [2]. Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Agilon (AGL) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Agilon and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential clai ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of agilon health, Inc. regarding potential securities fraud or unlawful business practices [1] - On August 4, 2025, agilon announced the resignation of Steven Sell as President, CEO, and Director, leading to a suspension of its full-year 2025 financial guidance [3] - Following the leadership change announcement, agilon's stock price dropped by $0.93, or 51.51%, closing at $0.88 per share on August 5, 2025 [3] Company Developments - The investigation by Pomerantz LLP focuses on whether agilon and its officers/directors engaged in misconduct [1] - The leadership change at agilon is part of a broader evaluation of actions to optimize operating performance amid market uncertainty [3] - The suspension of financial guidance indicates potential challenges in achieving previously set performance targets [3]

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Agilon Health, Inc. regarding possible violations of federal securities laws following significant leadership changes and financial disclosures that negatively impacted the company's stock price [1][3]. Company Developments - On August 4, 2025, Agilon Health, Inc. announced the resignation of its President, CEO, and Board Director, Steven Sell, from all positions [3]. - The company released its second-quarter 2025 financial results and withdrew its previously issued full-year 2025 earnings guidance, which surprised the market [3]. - Following these announcements, Agilon's share price fell by more than 27% in after-hours trading [3]. Legal Investigation - The investigation by Johnson Fistel focuses on whether Agilon failed to disclose material information to investors regarding the timing, circumstances, or implications of its leadership transition and guidance withdrawal, potentially violating federal securities laws [3].

Core Insights - Agilon Health (AGL) reported $1.39 billion in revenue for the quarter ended June 2025, reflecting a year-over-year decline of 5.9% [1] - The earnings per share (EPS) for the same period was -$0.25, compared to -$0.07 a year ago, indicating a significant deterioration in profitability [1] - The reported revenue was a surprise of -4.98% compared to the Zacks Consensus Estimate of $1.47 billion, while the EPS surprise was -127.27% against the consensus estimate of -$0.11 [1] Financial Performance Metrics - The average number of Medicare Advantage members was 498,000, slightly above the average estimate of 493,100 based on two analysts [4] - Other operating revenues were reported at $2.94 million, which is lower than the estimated $3.16 million by five analysts, representing a year-over-year decline of 7.4% [4] - Medical services revenues were $1.39 billion, compared to the average estimate of $1.46 billion from five analysts, also reflecting a year-over-year decrease of 5.9% [4] Stock Performance - Agilon's shares have returned -30% over the past month, contrasting with the Zacks S&P 500 composite's +0.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

agilon health (AGL) Q2 2025 Earnings Call August 04, 2025 05:30 PM ET Speaker0Good afternoon, and thank you for attending the Agilent Health second quarter twenty twenty May. My name is Jason. I'll be the moderator today. All lines will be muted during the presentation portion of call with an opportunity for questions and answers at the end. I would now like to pass the conference over to your host, Evan Smith.Speaker1Thank you, operator. Good afternoon, and welcome to the call. With me are Ron Williams, ou ...

2Q Earnings Presentation August 2025 Copyright © 2025 agilon health. Confidential internal document containing proprietary information. Do not distribute. Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-look ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00 ...

Financial Data and Key Metrics Changes - The company ended 2024 with approximately $440 million in cash, outperforming cash flow projections, and expects to burn about $110 million in 2025 [49] - The company aims to achieve cash flow breakeven by 2027, with several levers to pull, including contracting and cost control [50][52] Business Line Data and Key Metrics Changes - The company operates in two programs: Medicare Advantage (MA) and ACO REACH, with ACO REACH showing about $150 million in savings and a 13% gross savings rate [8] - Quality scores in the Medicare Advantage program are above 4 stars, with year two plus markets running at 4.25 or better, which is a key differentiator [6][7] Market Data and Key Metrics Changes - The company has seen a consistent cost trend of approximately 7% in 2023 and 2024, with a projected 5.3% for 2025 [30][31] - Utilization trends have remained consistent, with inpatient spend being a significant driver, particularly in oncology drugs [55] Company Strategy and Development Direction - The company is focused on transitioning from fee-for-service to value-based care, emphasizing the importance of the primary care physician-patient relationship [4][10] - The company is being measured in its growth strategy, with a reduction in new member classes for 2025 to 20,000, while planning for 30,000 to 45,000 in 2026 [15][70] Management's Comments on Operating Environment and Future Outlook - Management acknowledges a challenging macro environment but notes strong demand from physician groups and payers for the move to value-based care [14][19] - The company is focused on improving performance and reducing volatility, having exited two partnerships last year [41][46] Other Important Information - The company has reduced its Part D exposure from 70% to 30% of its membership for 2025, aiming to further decrease this by 2026 [44] - The company is implementing a new financial data pipeline to enhance revenue and claims information accuracy [34] Q&A Session Summary Question: What are the implications of the current risk adjustment process? - The company emphasizes the importance of the PCP-patient relationship and has a robust risk adjustment process in place, including a 100% chart review process [22][24] Question: How is the company managing utilization trends? - Utilization trends are consistent with expectations, with inpatient spend being a significant driver, particularly in oncology [55] Question: What is the company's strategy for physician partnerships? - The company maintains high net promoter scores from physicians, indicating strong engagement and satisfaction with the value-based care model [59][63]

Summary of Agilon Health (AGL) 2025 Conference Call Company Overview - Agilon Health focuses on transforming primary care by partnering with primary care physicians (PCPs) to manage total cost care and quality for senior populations, moving from fee-for-service to global risk models [2][3] Key Differentiators - Long-term exclusive partnerships with PCPs who have established relationships with their patients, averaging over ten years [2][3] - Transitioning patients and health plans into global risk models to enhance care management [3] Financial Performance and Cost Trends - For Q1, Agilon reported a 5.5% cost trend in year two plus markets, with adjustments indicating a normalized trend closer to 7% [6][7] - The company aims to focus on profitability while intentionally slowing growth, with a smaller member class in 2025 compared to previous years [10][11] Risk Management Strategies - Reduced Part D exposure from approximately 70% to below 30% of membership to mitigate financial risks associated with uncontrollable factors [17][19] - Implemented a no downside care management fee for first-year members to cover costs while transitioning to full risk [11][50] Quality Incentives and Programs - Agilon has seen a significant increase in quality incentives, with $25 million allocated for 2025, focusing on achieving higher star ratings [28][30] - The company is rolling out programs for chronic conditions such as palliative care, heart failure, and COPD, aiming to improve patient outcomes and reduce hospitalizations [33][37] Data and Forecasting Improvements - A new financial data pipeline was launched to enhance visibility into claims and improve forecasting accuracy, with 85% of membership now integrated [42][45] - The company is working to reduce variability in financial performance through better data management [46] ACO REACH Program - ACO REACH has been successful, generating $150 million in gross savings and is expected to expand due to positive outcomes [58][61] - The program is recognized as a model for future Medicare initiatives focusing on evidence-based prevention and alternative payment models [60][61] Long-term Vision - Agilon aims to strengthen its long-term relationships with PCPs, invest in clinical areas, and maintain disciplined growth strategies to adapt to macroeconomic changes [63] Additional Insights - The company is focused on reducing volatility in its operations and enhancing the quality of care provided to patients [21][22] - Agilon's approach emphasizes stability over potential margin expansion, particularly in managing uncontrollable costs [22][23]